Many cancer treatments are notoriously savage on the body. Drugs often attack both healthy cells and tumor cells, causing a plethora of side effects.
Immunotherapies that help the immune system recognize and attack cancer cells are no different. Though they have prolonged the lives of countless patients, they work in only a subset of patients. One study found that fewer than 30 percent of breast cancer patients respond to one of the most common forms of immunotherapy.
But what if drugs could be engineered to attack only tumor cells and spare the rest of the body?
Comments are closed.